Cargando…
Pulmonary hypertension, pulmonary embolism and COVID-19: A district general hospital experience from the UK
BACKGROUND: Preliminary data suggest that the prevalence of pulmonary hypertension (PH) in patients with COVID-19 is around 13%, but its prognostic role remains unclear. Approximately 3% of patients develop chronic thrombo-embolic pulmonary hypertension (CTEPH) following diagnosis of acute pulmonary...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9884629/ https://www.ncbi.nlm.nih.gov/pubmed/36705094 http://dx.doi.org/10.1177/14782715231152677 |
_version_ | 1784879758576713728 |
---|---|
author | Mahdi, Noor Nadeem, Iftikhar Ur Rasool, Masood Ul Munamm, Syed Ata Khatana, Usman Feroze Rashad, Faisal Babu, Anoop |
author_facet | Mahdi, Noor Nadeem, Iftikhar Ur Rasool, Masood Ul Munamm, Syed Ata Khatana, Usman Feroze Rashad, Faisal Babu, Anoop |
author_sort | Mahdi, Noor |
collection | PubMed |
description | BACKGROUND: Preliminary data suggest that the prevalence of pulmonary hypertension (PH) in patients with COVID-19 is around 13%, but its prognostic role remains unclear. Approximately 3% of patients develop chronic thrombo-embolic pulmonary hypertension (CTEPH) following diagnosis of acute pulmonary embolism (PE). It is recommended that patients are screened for CTEPH if they remain symptomatic 3 months following diagnosis of PE. The primary aim of the study was to assess the chances of persistent PH following PE secondary to COVID-19. METHODS: We conducted a retrospective cohort study at a District General Hospital (DGH) in the United Kingdom. All patients diagnosed with COVID-19 and PE between April 2020 and October 2021 were examined. Patients were divided into two groups:·COVID-19 and PE with comorbidities (excluding pre-existing PH) and·COVID-19 and PE without comorbidities. We compared the ECHO features suggestive of PH between the two groups at the time of diagnosis of PE and at 3 months following treatment. RESULTS: 80 patients were included in the study (49 with comorbidities and 31 with no comorbidities). Average age of comorbidities and no comorbidities groups were 73 years and 70 years, respectively. Average PaO(2)/FiO(2) ratio for comorbidities and no comorbidities groups were 170 and 195, respectively. Fourteen patients (13 with comorbidities and 1 with no comorbidities) died in total. Results showed that risk of persistent PH and subsequent mortality following PE in COVID-19 is 4.17 times and 1.32 times more in comorbidity group as compared to no comorbidity group, respectively (p < 0.001). CONCLUSION: Patients with comorbidities are at high risk of persistent PH and mortality due to PE secondary to COVID-19. |
format | Online Article Text |
id | pubmed-9884629 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-98846292023-01-30 Pulmonary hypertension, pulmonary embolism and COVID-19: A district general hospital experience from the UK Mahdi, Noor Nadeem, Iftikhar Ur Rasool, Masood Ul Munamm, Syed Ata Khatana, Usman Feroze Rashad, Faisal Babu, Anoop J R Coll Physicians Edinb Original Articles BACKGROUND: Preliminary data suggest that the prevalence of pulmonary hypertension (PH) in patients with COVID-19 is around 13%, but its prognostic role remains unclear. Approximately 3% of patients develop chronic thrombo-embolic pulmonary hypertension (CTEPH) following diagnosis of acute pulmonary embolism (PE). It is recommended that patients are screened for CTEPH if they remain symptomatic 3 months following diagnosis of PE. The primary aim of the study was to assess the chances of persistent PH following PE secondary to COVID-19. METHODS: We conducted a retrospective cohort study at a District General Hospital (DGH) in the United Kingdom. All patients diagnosed with COVID-19 and PE between April 2020 and October 2021 were examined. Patients were divided into two groups:·COVID-19 and PE with comorbidities (excluding pre-existing PH) and·COVID-19 and PE without comorbidities. We compared the ECHO features suggestive of PH between the two groups at the time of diagnosis of PE and at 3 months following treatment. RESULTS: 80 patients were included in the study (49 with comorbidities and 31 with no comorbidities). Average age of comorbidities and no comorbidities groups were 73 years and 70 years, respectively. Average PaO(2)/FiO(2) ratio for comorbidities and no comorbidities groups were 170 and 195, respectively. Fourteen patients (13 with comorbidities and 1 with no comorbidities) died in total. Results showed that risk of persistent PH and subsequent mortality following PE in COVID-19 is 4.17 times and 1.32 times more in comorbidity group as compared to no comorbidity group, respectively (p < 0.001). CONCLUSION: Patients with comorbidities are at high risk of persistent PH and mortality due to PE secondary to COVID-19. SAGE Publications 2023-01-27 2023-03 /pmc/articles/PMC9884629/ /pubmed/36705094 http://dx.doi.org/10.1177/14782715231152677 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Articles Mahdi, Noor Nadeem, Iftikhar Ur Rasool, Masood Ul Munamm, Syed Ata Khatana, Usman Feroze Rashad, Faisal Babu, Anoop Pulmonary hypertension, pulmonary embolism and COVID-19: A district general hospital experience from the UK |
title | Pulmonary hypertension, pulmonary embolism and COVID-19: A district general
hospital experience from the UK |
title_full | Pulmonary hypertension, pulmonary embolism and COVID-19: A district general
hospital experience from the UK |
title_fullStr | Pulmonary hypertension, pulmonary embolism and COVID-19: A district general
hospital experience from the UK |
title_full_unstemmed | Pulmonary hypertension, pulmonary embolism and COVID-19: A district general
hospital experience from the UK |
title_short | Pulmonary hypertension, pulmonary embolism and COVID-19: A district general
hospital experience from the UK |
title_sort | pulmonary hypertension, pulmonary embolism and covid-19: a district general
hospital experience from the uk |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9884629/ https://www.ncbi.nlm.nih.gov/pubmed/36705094 http://dx.doi.org/10.1177/14782715231152677 |
work_keys_str_mv | AT mahdinoor pulmonaryhypertensionpulmonaryembolismandcovid19adistrictgeneralhospitalexperiencefromtheuk AT nadeemiftikhar pulmonaryhypertensionpulmonaryembolismandcovid19adistrictgeneralhospitalexperiencefromtheuk AT urrasoolmasood pulmonaryhypertensionpulmonaryembolismandcovid19adistrictgeneralhospitalexperiencefromtheuk AT ulmunammsyedata pulmonaryhypertensionpulmonaryembolismandcovid19adistrictgeneralhospitalexperiencefromtheuk AT khatanausmanferoze pulmonaryhypertensionpulmonaryembolismandcovid19adistrictgeneralhospitalexperiencefromtheuk AT rashadfaisal pulmonaryhypertensionpulmonaryembolismandcovid19adistrictgeneralhospitalexperiencefromtheuk AT babuanoop pulmonaryhypertensionpulmonaryembolismandcovid19adistrictgeneralhospitalexperiencefromtheuk |